UNITED STATES
                      SECURITIES AND EXCHANGE COMMISSION
                             Washington, DC 20549



                                  FORM 10-QSB/A




[X]   Quarterly Report pursuant to Section 13 or 15(d) of the Securities
      Exchange Act of 1934

      For the quarterly period ended  November 30, 2005
                                      -----------------

[ ]   Transition Report pursuant to 13 or 15(d) of the Securities Exchange
      Act of 1934

      For the transition period                  to
                               ------------------   --------------------

      Commission File Number    333-107179
                            -----------------


                             XPENTION GENETICS, INC.
    ------------------------------------------------------------------------
       (Exact name of small Business Issuer as specified in its charter)


                               BAYVIEW CORPORATION
    ------------------------------------------------------------------------
     (Former name, former address and former fiscal year, if changed since
                                 last report)



          Nevada                                         98-0380519
---------------------------------             --------------------------------
(State or other jurisdiction of              (IRS Employer Identification No.)
 incorporation or organization)

10965 Elizabeth Drive
Conifer, CO                                               80433
----------------------------------------      --------------------------------
(Address of principal executive offices)           (Postal or Zip Code)


Issuer's telephone number, including area code:        (303) 908-4900
                                                ------------------------------


Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12
months (or for such shorter period that the issuer was required to file such
reports), and (2) has been subject to such filing requirements for the past 90
days [X] Yes [ ] No

State the number of shares outstanding of each of the issuer's classes of common
stock, as of the latest practicable date:  57,625,833 shares of $0.001 par value
common stock outstanding as of January 23, 2006.




<PAGE>

                          PART I FINANCIAL INFORMATION

Item 1.  Financial Statements


                             XPENTION GENETICS, INC.
                          (A Development Stage Company)



                                NOVEMBER 30, 2005
                            (Unaudited) and Restated


<PAGE>


                             XPENTION GENETICS, INC.
                          (A Development Stage Company)
                           Consolidated Balance Sheet
                                November 30, 2005
                            (Unaudited) and Restated

ASSETS

Current assets
   Cash and cash equivalents                                          $ 178,709
                                                                      ==========

LIABILITIES

Current liabilities
   Accounts payable                                                    $     60
   Accrued expenses                                                     104,651
   Note payable                                                         100,000
                                                                       ---------
    Total current liabilities                                           204,711
                                                                       ---------

STOCKHOLDERS' (DEFICIT)

Preferred stock, $0.001 par value, 10,000,000 shares authorized,
  none issued or outstanding                                                  -
Common stock, $0.001 par value, 100,000,000 shares authorized,
  57,625,833 shares issued and outstanding                               57,625
Additional paid-in capital                                              711,474
Deferred stock compensation                                            (184,500)
(Deficit) accumulated during the development stage                     (610,602)
                                                                      ----------
                                                                        (26,002)
                                                                      ----------
                                                                      $ 178,709
                                                                      ==========


 The accompanying footnotes are an integral part of these financial statements.

                                      F-1

<PAGE>

<TABLE>
<CAPTION>

                                             XPENTION GENETICS, INC.
                                          (A Development Stage Company)
                                      CONSOLIDATED STATEMENTS OF OPERATIONS
                      THREEAND SIX MONTHS ENDED NOVEMBER 30, 2005, (INCEPTION) OCTOBER 13,
                         2004 TO NOVEMBER 30, 2004, AND (INCEPTION) OCTOBER 13, 2004 TO
                                                NOVEMBER 30, 2005
                                            (Unaudited and Restated)


                                                                                         (Inception)          (Inception)
                                            Three Months Ended   Six Months Ended      October 13, 2004     October 13, 2004
                                            November 30, 2005    November 30, 2005   to November 30, 2004  to November 30, 2005
                                            -----------------------------------------------------------------------------------
<S>                                              <C>                <C>               <C>              <C>
Revenues                                          $            -     $           -     $           -   $                 -
                                                 ----------------   ---------------   ---------------  --------------------

Expenses
   Research and development                              102,665           181,425                 -               181,425
   General and administrative non cash stock
        compensation                                      92,250           184,500                 -               184,500
    General and administrative                            30,828            85,427            14,278               239,026
                                                 ----------------   ---------------   ---------------  --------------------
                                                         225,743           451,352            14,278               604,951
                                                 ----------------   ---------------   ---------------  --------------------

Operating (loss)                                        (225,743)         (451,352)          (14,278)             (604,951)
                                                 ----------------   ---------------   ---------------  --------------------

Other income (expense)
   Interest expense                                       (1,250)           (2,500)             (247)               (5,651)
                                                 ----------------   ---------------   ---------------  --------------------

Net (loss)                                        $     (226,993)   $     (453,852)    $     (14,525)   $         (610,602)
                                                 ----------------   ---------------   ---------------  --------------------

Basic and diluted
Weighted average shares outstanding                   57,625,833        57,529,658        56,842,500
                                                 ================   ===============   ===============

Basic and diluted:
  (Loss) per share                                $        (0.00)    $       (0.01)    $       (0.00)
                                                 ================   ===============   ===============

         The accompanying footnotes are an integral part of these financial statements.


                                              F-2
</TABLE>

<PAGE>

<TABLE>
<CAPTION>

                                        XPENTION GENETICS, INC.
                                     (A Development Stage Company)
                                 CONSOLIDATED STATEMENTS OF CASH FLOWS
                   SIX MONTHS ENDED NOVEMBER 30, 2005, (INCEPTION) OCTOBER 13, 2004
                                TO NOVEMBER 30, 2004, AND (INCEPTION)
                                OCTOBER 13, 2004 TO NOVEMBER 30, 2005
                                       (Unaudited and Restated)

                                                                                    (Inception)           (Inception)
                                                             Six Months Ended    October 13, 2004 to     October 13, 2004 to
                                                             November 30, 2005   November 30, 2004       November 30, 2005
                                                             ---------------------------------------------------------------
<S>                                                          <C>                 <C>                  <C>
Cash Flows From Operating Activities
   Net (loss)                                                 $      (453,852)   $         (14,525)   $            (610,602)
Adjustments to reconcile net (loss) to net cash
(used in) operating activities
      Stock compensation expense                                      184,500                    -                  184,500
      Prepaid expenses                                                      -              (21,250)                       -
      Accounts payable and accrued liabilities                         32,639                8,247                  104,711
                                                             -----------------   ------------------  -----------------------
Cash flows (used in) operating activities                            (236,713)             (27,528)                (321,391)
                                                             -----------------   ------------------  -----------------------


Cash Flows From Investing Activities
Cash flows provided by investing activities                                 -                    -                        -
                                                             -----------------   ------------------  -----------------------


Cash Flows From Financing Activities
   Proceeds from note payable                                               -              100,000                  100,000
   Proceeds from issuance of common stock                             400,000                  100                  400,100
                                                             -----------------   ------------------  -----------------------
Cash flows provided by financing activities                           400,000              100,100                  500,100
                                                             -----------------   ------------------  -----------------------

Increase in cash                                                      163,287               72,572                  178,709

Cash, beginning of period                                              15,422                    -                        -
                                                             -----------------   ------------------  -----------------------

Cash, end of period                                          $        178,709    $          72,572    $             178,709
                                                             =================   ==================  =======================

 The accompanying footnotes are an integral part of these financial statements.

                                      F-3
</TABLE>


<PAGE>

<TABLE>
<CAPTION>

                                             XPENTION GENETICS, INC.
                                          (A Development Stage Company)
                            CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)
                                INCEPTION (OCTOBER 13, 2004) TO NOVEMBER 30, 2005

                                                                                                     (Deficit)
                                                                                       Deferred      Accumulated
                                                 Common Stock        Additional         Stock       During the
                                              Shares       Amount    Paid in Capital  Compensation  Development Stage  Total
                                           ---------------------------------------------------------------------------------
<S>                                        <C>             <C>          <C>             <C>          <C>          <C>
Inception (October 13, 2004)                           -        $ -           $ -              $ -          $ -         $ -

Stock issued in acquition                     14,300,000        100             -                -            -         100

Recapitalization                              42,542,500          -             -                -            -           -
                                                                                                                          -
Net (loss)                                             -          -             -                -     (156,750)   (156,750)
                                           ---------------------------------------------------------------------------------

Balance, May 31, 2005                         56,842,500        100 #           -                -     (156,750)   (156,650)

June 15, 2005 Private placement                  333,333        333       399,667                -            -     400,000

June 28, 2005 stock issued for research
   & development                                 450,000        450       368,550         (369,000)           -           -

Deferred stock compensation                            -                        -          184,500            -     184,500

Reclassification                                       -     56,743       (56,743)               -            -           -

Net (loss)                                             -          -             -                -     (453,852)   (453,852)

                                           ---------------------------------------------------------------------------------
Balance November 30, 2005                     57,625,833   $ 57,626     $ 711,474       $ (184,500)  $ (610,602)  $ (26,002)
                                           =================================================================================

</TABLE>

 The accompanying footnotes are an integral part of these financial statements.


                                      F-4
<PAGE>

                             Xpention Genetics, Inc.
                          (A Development Stage Company)
                   Notes to Consolidated Financial Statements
                                November 30, 2005
                            (Unaudited and Restated)


NOTE 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Financial Statements

The accompanying unaudited financial statements of Xpention Genetics,  Inc. have
been prepared in accordance with generally  accepted  accounting  principles for
interim financial  information and with the instructions to Form 10-QSB and Rule
10-01 of  Regulation  S-X.  The  financial  statements  reflect all  adjustments
consisting of normal recurring adjustments, which, in the opinion of management,
are  necessary  for a fair  presentation  of the results for the periods  shown.
Accordingly,  they do not include all of the information and footnotes  required
by generally accepted accounting principles for complete financial statements.

These  financial  statements  should  be read in  conjunction  with the  audited
financial  statements and footnotes  included  thereto for the fiscal year ended
May 31, 2005, for Xpention  Genetics,  Inc. on Form 10KSB, as amended,  as filed
with the Securities and Exchange Commission.

The preparation of financial  statements in conformity  with generally  accepted
accounting principles requires management to make estimates and assumptions that
affect  the  reported  amounts  of assets  and  liabilities  and  disclosure  of
contingent  assets and  liabilities at the date of the financial  statements and
that effect the reported  amounts of revenues and expenses  during the reporting
period. Actual results could differ from those estimates.

Organization

Xpention Genetics,  Inc. (the Company) was incorporated in the State of Colorado
on October 13, 2004 and has been in the  development  stage since its inception.
In March 2005, the Company  entered the  biotechnology  industry to develop both
immunological  and molecular tests for cancer detection in animals and humans as
well as  therapeutic  vaccines and other  treatment  methods for both canine and
human cancers.  In March 2005 the Company changed its name to Xpention Genetics,
Inc. The Company has been in the  development  stage since its formation and has
not yet  realized  any  revenues  from its planned  operations.  The Company has
chosen May 31 as its fiscal year-end.

During March 2005 Bayview  issued  14,300,000  shares of its common stock to the
shareholders  of the  Xpention,  Inc.  in  exchange  for all of the  issued  and
outstanding  common  shares of  Xpention  pursuant to an  Agreement  and Plan of
Reorganization.  In addition,  Concurrent  with the exchange of shares,  Bayview
changed its name to Xpention Genetics, Inc.

                                      F-5

<PAGE>

                             Xpention Genetics, Inc.
                          (A Development Stage Company)
                   Notes to Consolidated Financial Statements
                                November 30, 2005
                            (Unaudited and Restated)

This   acquisition  of  Xpention,   the  accounting   acquirer,   by  Bayview  a
non-operating  entity,  is considered in substance a capital  transaction by the
issuance of  14,300,000  shares of common stock by Bayview for all of the issued
and  outstanding  common  shares of  Xpention,  and will be  accounted  for as a
reverse  acquisition,  and no  goodwill  or  other  intangible  assets  will  be
recorded.  On this basis, the historical financial statements as of and prior to
the acquisition date will represent the operations of Xpention.

Net (Loss) Per Common Share

The Company  follows SFAS 128,  "Earnings Per Share".  Basic earnings (loss) per
common share  calculations  are  determined by dividing net income (loss) by the
weighted average number of shares of common stock  outstanding  during the year.
Diluted earnings (loss) per common share calculations are determined by dividing
net income (loss) by the weighted  average  number of common shares and dilutive
common  share  equivalents  outstanding.   During  the  periods  when  they  are
anti-dilutive,  common  stock  equivalents,  if any, are not  considered  in the
computation.


NOTE 2. COMMITMENTS

On May 31, 2005, the Company  entered into a Research  Agreement with AMC Cancer
Research  Center  for  research  activities  for  the  development  of  the  p65
immunological  test for canines.  The estimated  cost for the project is $58,946
and the agreement expires on January 30, 2006.

On May 28, 2005, the Company  entered into a Research  Contract with  Genethera,
Inc. for research  activities for the development of the p65 molecular assay for
canines.  The contract  became  effective on May 28, 2005 and expires on May 30,
2006, and requires payments to Genethera of $20,000 per month.

On May 28, 2005,  the Company  entered into a Research  Agreement with Genethera
Inc. for research  activities for the development of the p65 molecular assay for
humans.  The agreement became effective on July 28, 2005 and expires on July 28,
2006 and requires payments to Genethera Inc. of $10,000 per month.


                                      F-6

<PAGE>

                             Xpention Genetics, Inc.
                          (A Development Stage Company)
                   Notes to Consolidated Financial Statements
                                November 30, 2005
                            (Unaudited and Restated)

On February 17, 2005,  the  Company's  wholly-owned  subsidiary  Xpention,  Inc.
entered into a License and Technology Licensing Agreement with the University of
Texas  M.D.  Anderson  Cancer  Center  (UTMDACC)  to  commercialize   technology
developed for cancer  detection in animals and humans.  The Company paid $50,000
for the  license  which was  expensed  during the year ended May 31,  2005.  The
Agreement  call for a 5.5% royalty to be paid to UTMDACC on the sale of products
utilizing the licensed technology.  In addition payments of $50,000 each are due
upon the  first  sales to both the  veterinary  market  and  human  market.  The
Agreement expires in February 2020.

On July 21, 2005,  the Company  entered into a Research  Agreement with Colorado
State  University for research  activities in connection with the development of
the p65  immunological  test for canines in which CSU will provide  canine blood
and tissue  specimens for use in clinical  trials.  The agreement  terminates on
July 1, 2006, and requires payments to CSU totaling $17,520.

On November 2, 2005,  the Company  amended its Research  Agreement with Colorado
state  University.  The  amendment  calls for CSU to  collect  additional  blood
samples for use by the Company in development of a canine cancer  detection test
and extends the  agreement  to November 1, 2006.  The Company  will pay Colorado
State  University an additional  $15,330 for the work performed  pursuant to the
amendment.


NOTE 3. COMMON STOCK

On June 28,  2005,  the Company  entered into a  Consulting  Agreement  with Dr.
Thomas Slaga for general scientific research assistance. The agreement continues
until at least  May 31,  2006.  The  Company  granted  Slaga  450,000  shares of
restricted  common  stock as  compensation  for such  services.  The shares were
valued  at their  fair  market  value on the date it was  agreed  they  would be
issued.  During the period  $102,665 has been charged to  operations as research
and  development  and  $184,500  has bee  recorded as deferred  compensation  at
November 30, 2005.


On June 15, 2005,  the Company  entered  into a  Subscription  Agreement  with a
private  investor for the sale of 333,333 shares of restricted  common stock for
cash at a price of $1.20 per share.


NOTE 4. NOTE PAYABLE

The Company's wholly-owned subsidiary entered into a loan agreement for $100,000
on November 12, 2004.  Interest  accrues at a rate of 5.0% per annum. The note's
original maturity date was November 12, 2005, however, on that date, the parties
agreed to extend the note to March 1, 2006.

NOTE 5. SUBSEQUENT EVENTS

On December 1, 2005,  the company  entered  into a Research  Agreement  with The
University of Texas Health  Science  Center at San Antonio  ("UTHSCSA")  whereby
UTHSCSA  agreed  to  perform   research   activities   for   development  of  an
immunological  test for canines.  This agreement replaces the Research Agreement
the Company  entered into with AMC Cancer  Research Center in May 2005 which has
been  relinquished by AMC. The agreement with UTHSCSA will permit the Company to
continue its  collaboration  with Dr.  Margaret  Hanausek who accepted a faculty
position at UTHSCSA.  The Company will pay $64,306 to UTHSCSA for work performed
pursuant to the Agreement.

                                      F-7

<PAGE>

                             Xpention Genetics, Inc.
                          (A Development Stage Company)
                   Notes to Consolidated Financial Statements
                                November 30, 2005
                            (Unaudited and Restated)

NOTE 6. CORRECTION OF AN ERROR

In March 2006,  the Company  determined  that the  Bayview/Xpention  transaction
should be treated as a recapitalization rather than as a purchase, the financial
statements  and  footnotes  have been  restated  to  reflect a  decrease  in the
inception to date net loss of $86,117 or $0.00 per share.













                                      F-8


<PAGE>

Item 2. Management's Discussion and Analysis or Plan of Operation

FORWARD LOOKING STATEMENTS

This quarterly report contains forward-looking statements that involve risks and
uncertainties.  We use words such as anticipate,  believe, plan, expect, future,
intend and similar expressions to identify such forward-looking  statements. You
should not place too much  reliance  on these  forward-looking  statements.  Our
actual results are likely to differ  materially from those  anticipated in these
forward-looking  statements  for many  reasons,  including the risks faced by us
described in this Risk Factors section and elsewhere in this annual report.

Plan of Operation

The Company, through its wholly-owned subsidiary,  holds the exclusive worldwide
license for  patented  technology  for the  detection of cancer based on a tumor
marker known as p65 which has been  demonstrated  to have elevated levels in the
blood of canine and human  cancer  conditions.  p65 is  believed to be a protein
required in the early  development  of numerous  cancers and appears  from early
research  to provide a strong  indication  of tumor  growth in both  canines and
humans.  It also appears to have a direct  correlation to tumor size/mass making
it a promising  marker for both early  detection of malignant tumor formation as
well as a useful tool for  monitoring  therapy  and  remission.  Initially,  the
Company plans to develop an immunological  test as well as a molecular assay for
detection  of  cancer  in  canines.  The  Company  also  plans to  develop  both
immunological  and  molecular  tests for  detection of human  cancers as well as
therapeutic treatments and vaccines.

During the interim  period ended  November 30, 2005,  the Company  continued its
research  activities  for the  development  of an  immunological  canine  cancer
detection  test as well as a  molecular  assay for  detection  of cancer in both
canines and humans,  all of which are being conducted by third parties on behalf
of the company.  In November  2005, the Company  amended its Research  Agreement
with Colorado State University in which CSU will, in addition to providing blood
and tissue samples for use in the development of the immunological canine cancer
detection  test,  also provide blood samples to be used in the  development of a
molecular  cancer  detection  test for canines.  The Company  also  continues to
evaluate various options for  commercialization of its products;  however, it is
not   anticipated   that  the  Company   will   generate   any   revenues   from
commercialization of its products during FY 2006.

Results of Operations for the Quarter Ended November 30, 2005


The Company did not earn any revenues  during the quarter period ending November
30, 2005.  For the  three-month  period  ending  November 30, 2005,  the Company
incurred expenses totaling $225,743 including research and development  expenses
of  $102,665,   administrative   expenses  of  $30,828  and  stock  compensation
(non-cash) of $92,250.

<PAGE>

The Company had a net loss for the quarter of ($226,993) in the quarter in 2005.
Net loss per share was nominal in the quarter in 2005.

RESULTS OF OPERATIONS FOR THE SIX-MONTH PERIOD ENDED NOVEMBER 30, 2005

The Company had no revenues in the six-month period.

For the six-month period ending November 30, 2005, the Company incurred expenses
totaling  $451,352  including  research  and  development  expenses of $181,425,
administrative   expenses  of  $85,427  and  stock  compensation  (non-cash)  of
$184,500.

Since  inception,  the Company has not  generated  any revenues and has incurred
expenses  totaling  $604,951  plus  interest  expense of $5,651 for a total loss
since inception of $610,602.


The Company  expects the trend of losses,  in the future,  will  continue at the
current rate until revenues can be achieved, which is not assured.

The Company  had  $178,709  in cash on hand at  November  30, 2005 and  accounts
payable and accrued liabilities totaling $104,711 and a note payable of $100,000
at November 30, 2005.

The Company issued 333,333 shares of stock at a price of $1.20 per share in June
2005  generating  $400,000  in cash,  the  proceeds  of which were used to cover
research  and  development  expenses as well as  administrative  expenses of the
Company during the period.

The Company has no capital  resources other than its capital stock with which to
raise more cash.

Item 3.  Controls and Procedures


The  Company  carried  out an  evaluation,  under the  supervision  and with the
participation  of the Company's  President and Chief Financial  Officer,  of the
effectiveness of the design and operation of the Company's  disclosure  controls
and procedures (as such term is defined in Rules  13a-14(c) and 15d-14(c)  under
the Securities  Exchange Act of 1934, as amended (the "Exchange  Act") as of the
quarter end of this  report.  Based upon such  evaluation,  such  officers  have
concluded that the Company's disclosure controls and procedures are effective in
alerting them, on a timely basis, to material  information  relating the Company
required to be included in this Form 10-QSB.


There have been no significant  changes to the Company's  internal controls over
financial reporting that have materially  affected,  or are reasonably likely to
materially effect, the Company's internal controls over financial reporting.


<PAGE>



                           PART II - OTHER INFORMATION

Item 1.  Legal Proceedings

The Company is not a party to any pending legal proceeding.  Current  management
is not aware of any threatened litigation, claims or assessments.


Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds

The Company did not issue any  securities  during the quarter ended November 30,
2005.


Item 3. Defaults Upon Senior Securities

         None.


Item 4. Submission of Matters to a Vote of Security Holders

         None.


Item 5. Other Information

         None.


Item 6. Exhibits

31    Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant
      to Section 302 of the Sarbanes-Oxley Act of 2002

32    Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant
      to Section 906 of the Sarbanes-Oxley Act of 2002

<PAGE>

                                   SIGNATURES

In accordance with the  requirements of the Exchange Act, the registrant  caused
this  report to be  signed on its  behalf  by the  undersigned,  thereunto  duly
authorized.

Dated:  April 19, 2006

                                        Xpention Genetics, Inc.

                                        /s/ David Kittrell
                                        ------------------------------
                                        David Kittrell, President